Normobaric Hyperoxia
Phase 2Small molecule
Normobaric Hyperoxia is one of 53 small molecule programs targeting Brain Injury. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Brain Injury
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Keppra
UCBApproved
Namenda
AbbVieApproved
Vimpat
UCBApproved
Buspar
Bristol-Myers SquibbApproved
Celexa
AbbVieApproved
Rozerem
TakedaApproved
Exelon
NovartisApproved
Vyvanse
TakedaApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke2 trials
Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke
Completed·—·N/A·NCT03620370·86 enrolled
Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)
Completed·—·Phase 2·NCT04681651·282 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Normobaric Hyperoxia. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGaylan Rockswold